The efficacy and tolerability of tauroursodeoxycholic acid (TUDCA) were studied in 133 patients with dyspepsia of varied origin: 69 patients took TUDCA as a single 500-mg dose or as 250 mg twice a day for 90 days; 64 controls received no drug. The two groups were comparable in age, sex, and associated diseases. Therapy was evaluated on the basis of symptom evolution reported by patients and measured on a semiquantitative severity scale from 0 (no symptoms) to 3 (severe symptoms). At the end of treatment, 71.1% of (TUDCA) patients had achieved complete disappearance of symptoms (19.4% of controls), and 18.4% had realized improvement (30.6% of controls). Our study suggests that TUDCA produces significant symptomatic improvement in patients with dyspepsia.
Tauroursodeoxycholic acid in the treatment of biliary dyspepsia / Di Mario, F.; Del Favero, G.; Scalon, P.; Meggiato, T.; Caroli, A.; Pilotto, A.. - In: ADVANCES IN THERAPY. - ISSN 0741-238X. - 11:1(1994), pp. 34-41.
Tauroursodeoxycholic acid in the treatment of biliary dyspepsia
Di Mario, F.;Pilotto, A.
1994-01-01
Abstract
The efficacy and tolerability of tauroursodeoxycholic acid (TUDCA) were studied in 133 patients with dyspepsia of varied origin: 69 patients took TUDCA as a single 500-mg dose or as 250 mg twice a day for 90 days; 64 controls received no drug. The two groups were comparable in age, sex, and associated diseases. Therapy was evaluated on the basis of symptom evolution reported by patients and measured on a semiquantitative severity scale from 0 (no symptoms) to 3 (severe symptoms). At the end of treatment, 71.1% of (TUDCA) patients had achieved complete disappearance of symptoms (19.4% of controls), and 18.4% had realized improvement (30.6% of controls). Our study suggests that TUDCA produces significant symptomatic improvement in patients with dyspepsia.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
